Abstract
In an effort to create a mechanism for addressing a critical need of providing medicines for economically developing countries, the Chiron Corporation and the Global Alliance for TB Drug Development have entered into an innovative public-private partnership. In the following interview, Craig Wheeler discusses the origins and nature of this agreement that could set a pattern for how corporations and nonprofit organizations can work together in drug development
Keywords No keywords specified (fix it)
Categories (categorize this paper)
DOI 10.1017/s0963180103124127
Options
Edit this record
Mark as duplicate
Export citation
Find it on Scholar
Request removal from index
Revision history

Download options

PhilArchive copy


Upload a copy of this paper     Check publisher's policy     Papers currently archived: 70,039
Through your library

References found in this work BETA

No references found.

Add more references

Citations of this work BETA

No citations found.

Add more citations

Similar books and articles

Industry, Innovation and Social Values.Harvey E. Bale - 2005 - Science and Engineering Ethics 11 (1):31-40.
Private-to-Private Corruption.Antonio Argandoña - 2003 - Journal of Business Ethics 47 (3):253 - 267.

Analytics

Added to PP index
2010-08-24

Total views
27 ( #422,941 of 2,505,269 )

Recent downloads (6 months)
1 ( #416,705 of 2,505,269 )

How can I increase my downloads?

Downloads

My notes